Proenkephalin is processed in a projection-specific manner in the rat central nervous system (posttranslational 27, 1986 ABSTRACT The biosynthesis and posttranslational proteolytic processing of proenkephalin was studied in three projection systems in the rat central nervous system-the caudate-putamen to the globus pallidus, the paraventricular nucleus of the hypothalamus to the median eminence, and the mossy fiber system of the granule cells of the hippocampus. By using the techniques of in vivo radiolabeling and sequential high-performance liquid chromatographic purification coupled with chemical modification, the biosynthesis of six radio-
Synaptically active neuropeptides, like other biologically active peptides, are synthesized as part of a larger precursor protein, which then undergoes a series of proteolytic cleavages and enzymatic modifications to liberate the mature peptide. Moreover, these precursors have been shown to contain more than one biologically active peptide, as in proopiomelanocortin, the common precursor to endorphins and melanotropins (1) , and have been termed polyproteins (2) . The precursor protein to another family of opioid peptides, the enkephalins, is also a polyprotein of considerable complexity. A large number of enkephalin-containing peptides have been identified in the adrenal gland (e.g., refs. [3] [4] [5] [6] and in the brain (7, 8) . Inspection of the cDNA-derived proenkephalin primary sequence (9) suggests that these peptides are generated through selective proteolysis that is directed by paired basic amino acid residues (2, 10, 11) and possibly by the location of single arginine residues (12) . The ability to produce a range of enkephalin peptides has profound implications for the regulatory actions of enkephalins in the central nervous system (CNS) because it suggests that diverse physiological roles for enkephalinergic neurons can be determined by the specific enkephalin peptides that are liberated from proenkephalin for synaptic release. However, such a possibility can only be inferential based solely on static measurements of tissue peptide levels.
The present experiments were designed to critically test the hypothesis that different CNS projection systems differentially liberate specific [Met] enkephalin peptides through differential proteolysis by the direct demonstration of the delivery of newly synthesized, biochemically identified products of processing to specific terminal fields. To this end we have used dynamic measurements of the in vivo biosynthesis and processing of proenkephalin in three specific, anatomically well-defined projections in the rat brain-i.e., the caudate-putamen to the globus pallidus (13), the paraventricular nucleus of the hypothalamus to the median eminence (14) , and the mossy fiber system of the granule cells of the hippocampus (15) . We report here that the posttranslational processing of proenkephalin differs in these three projection systems.
MATERIALS AND METHODS
Materials. Male Sprague-Dawley rats (200-250 g) were used for these studies. Peptide standards were from Bachem Fine Chemicals (Torrance, CA); HPLC columns were from Vydac (Hesperia, CA). Acetonitrile, formic acid, H202, and Scinti-Verse II were from Fisher. Trifluoroacetic acid was from Sigma. Triethylamine was from Baker. [35S]Methionine was from New England Nuclear (specific activity, >1000 Ci/mmol; 1 Ci = 37 GBq). Model 2001 osmotic minipumps were from Alzet.
Cannulation and Label Administration. The cannulation and labeling protocol were similar to those described elsewhere (16) . Briefly, rats were cannulated in the right caudateputamen (A 0.9, L 2.5, V 4.0, mouth bar set at +5, with respect to bregma) with a pair of stainless steel cannulae.
Following an overnight recovery period, 500 pACi of [35S]_ methionine was infused through the cannulae over a period of 4 hr using an Alzet osmotic minipump delivery system at a flow rate of 1 Ml/hr. Artificial extracellular fluid was pumped through the cannulae for an additional 2 hr. For hypothalamic cannulation the parameters were A 0.4, L 0.0, V 7.3; for hippocampal cannulations a single cannula was used: P 3.8, L 2.5, V 2.8, with the mouth bar set at 0.0. In all animals, proper cannula(e) placement was verified in the region of the cell bodies by visual inspection. The 2-hr chase time is allowed for peptide synthesis, processing, and transport and is equal to at least four transport times from the cell bodies to the terminal fields for each projection.
Tissue Harvest and Peptide Purification. Following the labeling period, animals were killed by decapitation and the regions of cell bodies and terminal fields were dissected and then homogenized in the presence of 25 pug of each carrier peptide in the buffer of Bennet et al. (17) at 40C. The samples were concentrated on a Speed-Vac drier and applied to the initial HPLC gradient that used a buffer system of 0.1 M phosphoric acid/0. 1 M sodium phosphate, pH 2.5, and acetonitrile. The gradient was a three-step linear gradient and the flow rate was 1 ml/min. One-minute fractions were collected. The carrier peptide-containing fractions were collected and lyophilized, and the peptides were converted to the methionine sulfoxide forms with 1% H202 (18) and were then applied to the second HPLC systems (18) . The gradients were exponentially shaped and the buffer systems were triethylammonium phosphate (16) (18) . BAM 18P, peptide E, and metorphamide were not treated further. The samples were then applied to exponentially shaped gradients in a buffer system of 0.1% trifluoroacetic acid and 0.1% trifluoroacetic acid in acetonitrile (18) . The entire fraction was taken for radioactivity determination. All peptides were purified to constant radiochemical specific activity (dpm/,ug of carrier peptide) by this procedure.
RESULTS
To investigate the biosynthesis and processing of proenkephalin, we examined the de novo synthesis of six [Met]enkephalin peptides:
[Met5,Arg6,Phe7]Enk, metorphamide, peptide E, and the recently described BAM 18P (19) . These peptides were chosen because each is contained only within proenkephalin (see Fig. 1 ), and each has been identified in brain and has been shown to possess opiate binding activity (3, 4, 8) . For these studies we used our previously described technique of investigating neuropeptide biosynthesis in vivo (16)-i.e., radiolabeled amino acid is delivered discretely to the cell bodies of interest through stereotaxically implanted cahnulae and radiolabeled peptides are harvested from terminal fields and purified through three sequential HPLC purification steps, during the course of which specific chemical modifications are carried out. The data shown in Figs. 2 and 3 are representative of the data obtained from experiments investigating enkephalin biosynthesis in the caudate-putamen to globus pallidus projection system.
As Fig. 2 illustrates, each of the enkephalin peptides was well separated on the initial HPLC purification step. However, equally evident is the finding that clear peaks of radioactivity that comigrated with each ofthe carrier peptides
were not apparent at this first step despite the fact that the globus pallidus contains among the highest concentrations of enkephalin in the rat brain (8, 9) . Therefore, the fractions containing the carrier peptides were separately collected, subjected to chemical modification [formation of the methionine sulfoxide and then the methionine sulfone forms of the peptides (18)], and further purified through two additional HPLC steps using different buffer systems and gradients. As is shown in Fig. 3 [Met5,Arg6,Phe7]Enk above essentially flat baselines. Each of these peptides had been purified to constant radiochemical specific activity. The biosynthetic data obtained from several animals were compared by arbitrarily setting the amount of radioactivity present in [Met5,Arg6,Phe7]Enk equal to one and then expressing the data as the ratio of the radioactivity present in each of the peptides (see Table 1 ). In no case was the amount of [Met5,Arg6,Gly7,Leu8]Enk <70% of that of [Met5,Arg6,Phe7]Enk. Note also that because each peptide contains one methionine residue, the ratio of radioactivity is also a molar ratio. However, as is also shown in Fig. 3 , a clear peak of radioactivity that comigrated with the carrier peptide was much less evident for BAM 18P. Indeed, the molar ratios of BAM 18P, metorphamide, and peptide E were each found to be <12% of [Met5,Arg6,Phe7]Enk.
Using identical methods, enkephalin biosynthesis was investigated in the hypothalamic projection system. Several interesting differences in the products of proenkephalin processing were found between the hypothalamus and the striatum. Again, after the initial HPLC purification step, no clear peaks of radioactivity were found to comigrate with the carrier peptides (not shown); however, following the final HPLC step, clear peaks of radioactivity were found to Fig. 2 Fig. 4 ). As Fig. 4 acid-soluble radioactivity harvested from the terminal fields was 0.26% ± 0.09% for globus pallidus, 0.15% ± 0.03% for median eminence, and 0.003% ± 0.001% for mossy fibers. *Different from median eminence at P < 0.025 and from mossy fibers at P = 0.025. tDifferent from median eminence at P < 0.001 and from mossy fibers at P < 0.01. tDifferent from median eminence at P = 0.050 and from mossy fibers at P = 0.1. Similarly, enkephalin biosynthesis was studied in the mossy fibers of the hippocampus-i.e., radiolabeled methionine was infused unilaterally above the granule cells in the hilus and radiolabeled enkephalins were purified from the terminal fields of the mossy fibers. The data from these studies are summarized in Table 1 (26) and in the guinea pig ileum assay (3 (27) . The (34) ; (iii) an enzyme that is responsible for cleavage at single arginine residues, which may be similar to the enzyme involved in dynorphin processing (12) , and which, in concert with iv, an amide-forming enzyme (35, 36) , generates metorphamide; and (v) the postulated enzyme, which is responsible for cleavage of the precursor at the paired arginine residues in BAM 18P.
